Friday, December 14, 2018 12:23:00 PM
A public acquirer could easily benefit from ImmunoCellular Therapeutics prior reporting compliance, ie., all Financials and Filings were current up to the date the company deregistered, and a private acquirer could file a FORM 10 to register their amalgamated companies with the SEC, benefitting from ImmunoCellular Therapeutics SEC compliance before the company deregistered.
Very low risk with this stock, as I see it.
All Financials and Filings up to Nov. 6,2018:
https://www.sec.gov/cgi-bin/browse-edgar?company=ImmunoCellular+Therapeutics&owner=exclude&action=getcompany
To bite the worm of incite is to bite the HOOK of the antagonist . They win .
North Bay Resources Commences Operations at Bishop Gold Mill, Inyo County, California; Engages Sabean Group Management Consulting • NBRI • Sep 25, 2024 9:15 AM
CEO David B. Dorwart Anticipates a Bright Future at Good Gaming Inc. Through His Most Recent Shareholder Update • GMER • Sep 25, 2024 8:30 AM
Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • BLOZF • Sep 24, 2024 8:50 AM
Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • INTV • Sep 24, 2024 8:45 AM
Avant Technologies Accelerates Creation of AI-Powered Platform to Revolutionize Patient Care • AVAI • Sep 24, 2024 8:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM